High-Flying Novo Nordisk Dips On Disappointing Data for Weight-Loss Pill
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people lose weight in the mid-stage study,
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...
9don MSN
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Novo Nordisk (NVO) stock is falling Friday morning after the pharmaceutical giant shared that additional weight loss tied to ...
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback